The two studies linked here do not investigate theobromine or respiratory health in any capacity — both are epidemiological studies focused on SARS-CoV-2 genomic surveillance and wastewater-based COVID-19 monitoring methodology, with no examination of theobromine as a compound or its effects on lung function, airway inflammation, or any other respiratory outcome. As a result, no evidence-based summary connecting theobromine to respiratory health can be drawn from this literature. Readers interested in this topic should consult studies specifically designed to examine theobromine's pharmacological effects on the respiratory system, such as trials investigating its role as a cough suppressant or bronchodilator. The current linked evidence base does not support any conclusions about theobromine and respiratory health.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Population Normalization in SARS-CoV-2 Wastewater-Based Epidemiology: Implica... | Other | 2022 | Neutral | 90 |
| Predominance of the SARS-CoV-2 lineage P.1 and its sublineage P.1.2 in patien... | Other | 2021 | Neutral | 85 |